20 https://www.biospace.com/articlesrss/ Tue, 23 May 2023 03:57:04 -0500 Tue, 23 May 2023 03:57:04 -0500 BioSpace ]]>Data from a Phase III trial of apraglutide for a type of short bowel syndrome with intestinal failure is expected by the end of the year. It is also in a Phase II study for acute graft-versus-host disease. https://www.biospace.com/article/ironwood-to-pay-1b-to-acquire-vectivbio-late-stage-digestive-therapy/ Tue, 23 May 2023 00:00:00 -0500 https://www.biospace.com/article/ironwood-to-pay-1b-to-acquire-vectivbio-late-stage-digestive-therapy/ Innate Pharma SA announced that members of its senior management team are scheduled to participate in the following upcoming conferences. https://www.biospace.com/article/releases/innate-pharma-to-participate-in-upcoming-june-2023-investor-conferences/ Tue, 23 May 2023 00:06:00 -0500 https://www.biospace.com/article/releases/innate-pharma-to-participate-in-upcoming-june-2023-investor-conferences/ TISSIUM announced it has closed a Series D round of financing, raising €50 million from new and existing international investors, including Fonds Stratégique des Transitions, managed by ISALT, Merieux Developpement and returning Cathay Health, Credit Mutuel Innovation and Sofinnova Partners. https://www.biospace.com/article/releases/tissium-raises-50m-in-series-d-funding-to-finance-its-commercial-launch-and-platform-extension/ Tue, 23 May 2023 00:45:00 -0500 https://www.biospace.com/article/releases/tissium-raises-50m-in-series-d-funding-to-finance-its-commercial-launch-and-platform-extension/ Propanc Biopharma, Inc., a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced that the Company’s board of directors has approved a reverse stock split of its common stock at a ratio of 1 post-split share for every 1,000 pre-split shares. https://www.biospace.com/article/releases/propanc-biopharma-announces-reverse-stock-split-may-23-2023/ Tue, 23 May 2023 00:46:00 -0500 https://www.biospace.com/article/releases/propanc-biopharma-announces-reverse-stock-split-may-23-2023/ Guardant Health, Inc., a leading precision oncology company, announced the pricing of an upsized underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $28.00 per share, before deducting underwriting discounts and commissions. https://www.biospace.com/article/releases/guardant-health-announces-pricing-of-upsized-public-offering-of-common-stock-may-23-2023/ Tue, 23 May 2023 00:06:00 -0500 https://www.biospace.com/article/releases/guardant-health-announces-pricing-of-upsized-public-offering-of-common-stock-may-23-2023/ Agile Therapeutics, Inc., a women's healthcare company, announced the pricing of its public offering of an aggregate of 1,896,286 shares of its common stock, together with accompanying common stock warrants, at a public offering price of $3.9551 per share and accompanying warrants. https://www.biospace.com/article/releases/agile-therapeutics-announces-pricing-of-7-5-million-public-offering-/ Tue, 23 May 2023 00:00:00 -0500 https://www.biospace.com/article/releases/agile-therapeutics-announces-pricing-of-7-5-million-public-offering-/ Spago Nanomedical AB announced that the final step in the preparations for the clinical phase I/IIa trial in cancer patients, Tumorad-01, with its leading candidate drug 177Lu-SN201 has begun in Australia. https://www.biospace.com/article/releases/spago-nanomedical-has-submitted-application-to-start-tumorad-r-clinical-phase-i-iia-study/ Tue, 23 May 2023 00:20:00 -0500 https://www.biospace.com/article/releases/spago-nanomedical-has-submitted-application-to-start-tumorad-r-clinical-phase-i-iia-study/ Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, announced multiple presentations to take place at the American Diabetes Association Annual Meeting from June 23–26, 2023 in San Diego, CA. https://www.biospace.com/article/releases/carmot-therapeutics-to-present-clinical-data-from-its-pipeline-of-treatments-for-obesity-and-diabetes-at-the-83rd-american-diabetes-association-scientific-sessions/ Tue, 23 May 2023 00:00:00 -0500 https://www.biospace.com/article/releases/carmot-therapeutics-to-present-clinical-data-from-its-pipeline-of-treatments-for-obesity-and-diabetes-at-the-83rd-american-diabetes-association-scientific-sessions/ Net sales amounted to kSEK 520 (182) divided by sales of tests kSEK 379 (122) and royalties kSEK 141(60). https://www.biospace.com/article/releases/immunovia-publishes-interim-report-for-january-march-2023/ Tue, 23 May 2023 00:06:00 -0500 https://www.biospace.com/article/releases/immunovia-publishes-interim-report-for-january-march-2023/ OMRON Healthcare Co., Ltd. based in Muko City, Kyoto Prefecture, Japan, is proud to announce the celebration of its 50th anniversary in blood pressure monitor production this year. https://www.biospace.com/article/releases/omron-healthcare-celebrates-50-years-of-blood-pressure-monitor-history/ Tue, 23 May 2023 00:06:00 -0500 https://www.biospace.com/article/releases/omron-healthcare-celebrates-50-years-of-blood-pressure-monitor-history/ AnaMar, a clinical-stage biotech company developing a first-in-class, peripheral 5-HT2B receptor antagonist, AM1476, as a pan anti-fibrotic medicine, announces positive results from its Phase I study, and the completion of Phase II enabling pre-clinical studies for its initial orphan indication in systemic sclerosis characterized by lung and skin fibrosis. https://www.biospace.com/article/releases/anamar-announces-positive-phase-i-data-for-its-phase-ii-ready-compound-am1476-for-treating-fibrosis/ Tue, 23 May 2023 00:00:00 -0500 https://www.biospace.com/article/releases/anamar-announces-positive-phase-i-data-for-its-phase-ii-ready-compound-am1476-for-treating-fibrosis/ BioInvent International AB announces the appointment of Ingunn Munch Lindvig as Senior Vice President Regulatory Affairs. https://www.biospace.com/article/releases/bioinvent-strengthens-management-with-appointment-of-ingunn-munch-lindvig-as-senior-vice-president-regulatory-affairs/ Tue, 23 May 2023 00:50:00 -0500 https://www.biospace.com/article/releases/bioinvent-strengthens-management-with-appointment-of-ingunn-munch-lindvig-as-senior-vice-president-regulatory-affairs/ Veristat, a scientific-minded global clinical research organization and regulatory consultancy, shared the addition of three seasoned leaders to Veristat’s Executive team. https://www.biospace.com/article/releases/veristat-taps-accomplished-industry-leaders-to-support-growth-and-innovation/ Tue, 23 May 2023 00:46:00 -0500 https://www.biospace.com/article/releases/veristat-taps-accomplished-industry-leaders-to-support-growth-and-innovation/ Valo Therapeutics Oy, the developer of novel, adaptable immunotherapies for cancer, announces that the first patient has been treated in its Phase I trial of PeptiCRAd-1 in three tumor types. https://www.biospace.com/article/releases/valo-therapeutics-announces-first-patient-dosed-with-pepticrad-1-innovative-immuno-oncology/ Tue, 23 May 2023 00:00:00 -0500 https://www.biospace.com/article/releases/valo-therapeutics-announces-first-patient-dosed-with-pepticrad-1-innovative-immuno-oncology/ ]]>With Friday’s approval, Epkinly edges out Roche’s bi-specific antibody glofitamab, which is also being proposed for diffuse large B-cell lymphoma. https://www.biospace.com/article/abbvie-genmab-score-fda-nod-for-dlbcl-as-blood-cancer-space-heats-up/ Mon, 22 May 2023 00:00:00 -0500 https://www.biospace.com/article/abbvie-genmab-score-fda-nod-for-dlbcl-as-blood-cancer-space-heats-up/ ]]>Sanofi and Regeneron reported positive results for the anti-inflammatory drug in a chronic obstructive pulmonary disease trial. The companies hope to see approval before a 2024 read-out of a second trial. https://www.biospace.com/article/phase-iii-results-prime-dupixent-as-first-potential-biologic-approval-for-copd/ Mon, 22 May 2023 00:00:00 -0500 https://www.biospace.com/article/phase-iii-results-prime-dupixent-as-first-potential-biologic-approval-for-copd/ ]]>The topical treatment Vyjuvek got the FDA’s greenlight, making it the first redosable gene therapy and the first therapeutic for the rare skin disease dystrophic epidermolysis bullosa. https://www.biospace.com/article/krystal-gets-first-fda-approval-for-redosable-gene-therapy-rare-skin-disease/ Mon, 22 May 2023 00:00:00 -0500 https://www.biospace.com/article/krystal-gets-first-fda-approval-for-redosable-gene-therapy-rare-skin-disease/ ]]>The 61-patient study met the primary endpoint of improved physiologic liver function and secondary endpoints, which included established non-alcoholic steatohepatitis biomarkers, Hepion reported Monday. https://www.biospace.com/article/hepion-claims-phase-ii-nash-victory-following-intercept-s-adcomm-defeat-/ Mon, 22 May 2023 00:00:00 -0500 https://www.biospace.com/article/hepion-claims-phase-ii-nash-victory-following-intercept-s-adcomm-defeat-/ ]]>ReCode plans to use its SORT LNP genetic medicines delivery technology to treat CF and PCD patients who don’t respond to current treatments. https://www.biospace.com/article/recode-a-new-contestant-in-the-mrna-race-/ Mon, 22 May 2023 00:00:00 -0500 https://www.biospace.com/article/recode-a-new-contestant-in-the-mrna-race-/ ]]>The extensive discussion between the FDA’s advisory committee, company representatives and other interested parties could serve as a cautionary tale to developers of future gene therapies. https://www.biospace.com/article/opinion-sarepta-enters-uncharted-territory-with-adcomm-approval/ Mon, 22 May 2023 00:00:00 -0500 https://www.biospace.com/article/opinion-sarepta-enters-uncharted-territory-with-adcomm-approval/